1 / 15

Medication-Assisted Therapy

Medication-Assisted Therapy. Vivitrol. Division of Addiction Services Vivitrol Pilot . Overall DAS has a goal to develop a system of care that consistently offers clients the means to enter and sustain recovery

nowles
Download Presentation

Medication-Assisted Therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Medication-Assisted Therapy Vivitrol

  2. Division of Addiction Services Vivitrol Pilot • Overall DAS has a goal to develop a system of care that consistently offers clients the means to enter and sustain recovery • To this end DAS hopes to promote evidence based practices in the treatment of addictions • One initiative in this area is the planned Vivitrol pilot

  3. Division of Addiction ServicesVivitrol Pilot • Objective: • Support and extend continuous abstinence • Afford client opportunity • stabilization during treatment • acquire skills necessary to independently support recovery • transition into Recovery Zone

  4. Medication Assisted TherapyWhat is Vivitrol? Vivitrol is injectable Naltrexone with the following benefits: • Works well with counseling • Reduces cravings • Decreased impulsivity • Enhanced motivation • Improved treatment adherence • Single injection is effective for four weeks - Eliminates daily adherence decisions • Rapid onset of therapeutic effect in the first 2 days • Generally well tolerated with a demonstrated safety profile

  5. Vivitrol • Injectable form of Naltrexone • Once monthly dosing • FDA approved 2006 • Manufactured by Alkermes, Inc. • An Evidence Based Practice - SAMHSA Treatment Improvement Protocol #49: “Incorporating Alcohol Pharmacology into Medical Practice”

  6. Journal of Substance Abuse TreatmentJanuary 2009 “The Effects of Extended-release Naltrexone on Holiday Drinking in Alcohol-dependent Patients” With Vivitrol: • Better able to avoid episodes of heavy drinking during the holidays • Opportunity to deal with the special dangers of alcohol-impaired driving

  7. Choosing the Pilot Cohort DUI Population • Higher rate of alcohol as primary drug of choice • Looking for evidence of a decrease in DUI offenses (clients don’t go on to offend again) • Supported with DUII funding

  8. Choosing the Pilot Cohort Of clients with primary alcohol diagnosis admitted in NJSAMS: 3,700 admitted to detoxification 985- at least one DUI offense 423- more than one episode of detoxification 288- both multiple detoxification and multiple DUI offenses

  9. DAS IDP Vivitrol Pilot • Goals for DUI offender participants: • Period of stabilization in which to embark upon recovery • Reduction or elimination of DUI offenses • Decrease of additional detoxification episodes

  10. DAS IDP Vivitrol Pilot • 100 voluntary participants • DUI multiple offender • Alcohol Dependent Diagnosis • DUII eligible • Present and admitted for alcohol detoxification

  11. Supplemental Services Available to Pilot Participants • Physician and Patient Education • Up to six injections per client while in treatment • Medical visits

  12. DAS IDP Vivitrol Pilot How It Works • DUII Network of Vivitrol Providers as a subset of DUII Network who will be trained and eligible for reimbursement for pilot services • Clients receive initial injection at discharge from detoxification • Follow up injections and continuing care treatment at a DUII/ Vivitrol Provider Agency • DUII will reimburse for the medication and all services

  13. Study the Impact • Pursuing offer from CSAT to assist with outcome study • Study will assess • Client outcomes • Costs

  14. Questions/Feedback

  15. Who to Contact? Vicki Fresolone Director of Treatment Services Vicki.Fresolone@dhs.state.nj.us Ann Wanamaker Assistant Chief, Intoxicated Driving Program Ann.Wanamaker@dhs.state.nj.us Lisa Mojer-Torres, Consumer Advocate Lisa.Mojer-Torres@dhs.state.nj.us

More Related